JP2024536721A5 - - Google Patents
Info
- Publication number
- JP2024536721A5 JP2024536721A5 JP2024514047A JP2024514047A JP2024536721A5 JP 2024536721 A5 JP2024536721 A5 JP 2024536721A5 JP 2024514047 A JP2024514047 A JP 2024514047A JP 2024514047 A JP2024514047 A JP 2024514047A JP 2024536721 A5 JP2024536721 A5 JP 2024536721A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- alkyl
- oligonucleotide conjugate
- conjugate according
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240472P | 2021-09-03 | 2021-09-03 | |
| US63/240,472 | 2021-09-03 | ||
| US202263314855P | 2022-02-28 | 2022-02-28 | |
| US63/314,855 | 2022-02-28 | ||
| PCT/US2022/042365 WO2023034515A2 (en) | 2021-09-03 | 2022-09-01 | Delivery of anitsense oligomers by mirror image peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536721A JP2024536721A (ja) | 2024-10-08 |
| JP2024536721A5 true JP2024536721A5 (cg-RX-API-DMAC10.html) | 2025-10-16 |
Family
ID=83598723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514047A Pending JP2024536721A (ja) | 2021-09-03 | 2022-09-01 | 鏡像ペプチドによるアンチセンスオリゴマーの送達 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250011777A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4387676A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024536721A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023034515A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026526969A (ja) * | 2023-08-02 | 2026-08-10 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンスオリゴマー送達のための非標準細胞透過性ペプチド |
| WO2026080471A2 (en) | 2024-10-07 | 2026-04-16 | Flagship Pioneering Innovations Vi, Llc | Compositions of trem conjugates and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| LT2735568T (lt) | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| TWI726844B (zh) * | 2014-05-23 | 2021-05-11 | 美商健臻公司 | 胜肽載體上之多重寡核苷酸部分 |
| EA201891419A1 (ru) * | 2015-12-15 | 2019-01-31 | Сарепта Терапьютикс, Инк. | Пептид-олигонуклеотидные конъюгаты |
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
-
2022
- 2022-09-01 WO PCT/US2022/042365 patent/WO2023034515A2/en not_active Ceased
- 2022-09-01 EP EP22778123.4A patent/EP4387676A2/en active Pending
- 2022-09-01 US US18/688,144 patent/US20250011777A1/en active Pending
- 2022-09-01 JP JP2024514047A patent/JP2024536721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI94419B (fi) | Menetelmä terapeuttisesti käyttökelpoisen membraaniankkuri-vaikuttava-ainekonjugaatin valmistamiseksi | |
| AU2024201004A1 (en) | Process for preparing a GIP/GLP1 dual agonist | |
| RU2279883C2 (ru) | Гибридные полипептиды с усиленными фармакокинетическими свойствами | |
| Soukchareun et al. | Preparation and characterization of antisense oligonucleotide-peptide hybrids containing viral fusion peptides | |
| EP0968227B1 (en) | Dimeric cationic lipids on dicystine basis | |
| KR102634762B1 (ko) | 알파-v 베타-6 인테그린 리간드 및 그의 용도 | |
| US20240390508A1 (en) | Human transferrin receptor binding peptide-drug conjugate | |
| WO1998039358A9 (en) | Oligomeric cationic lipids | |
| CZ296014B6 (cs) | Způsob vazby zbytku aminokyseliny na peptidový řetězec | |
| JPH06510028A (ja) | ランチオニン架橋ペプチド | |
| NO334155B1 (no) | Anvendelse av konjugater, for transportering av molekyler via bisykliske membraner og for fremstilling av et medikament og/eller diagnostisk middel samt fremgangsmåte for transport in vitro | |
| JPH0317098A (ja) | 合成ペプチド及びその塩並びにそれらの製造法 | |
| JP2024536721A (ja) | 鏡像ペプチドによるアンチセンスオリゴマーの送達 | |
| DE602004008460T2 (de) | Peptidanaloga, die wenigstens einen aminoacy-aza-beta-3-rest enthalten, und deren verwendung, insbesondere für die therapie | |
| US8278265B2 (en) | Methods, kits and compositions comprising crotamine | |
| Baker et al. | Novel reagents and reactions for drug design | |
| US7038037B2 (en) | Method for sequential support-bound synthesis of conjugated oligomeric compounds | |
| Giorgio et al. | Synthesis of a new class of HIV-1 inhibitors | |
| Leban et al. | Potent Gastrin-Releasing Peptide (GRP) Antagonists Derived from GRP (19-27) with a C-Terminal DPro. PSI.[CH2NH] Phe-NH2 and N-Terminal Aromatic Residues | |
| Castell et al. | [D‐Ala2, Phe (p‐NO2) 4, Leu5] Enkephalin Amide and Nα‐[D‐Ala2, Leu5]‐Enkephalyl‐Nε‐Acetyl‐Lysine Amide: Synthesis and Biological Properties of Prospective Enkephalin Cooperative‐Affinity and Photoaffinity Labels. Preliminary communication | |
| US20250171776A1 (en) | Non-canonical cell-penetrating peptides for antisense oligomer delivery | |
| Mazzucco et al. | Synthesis of lipopeptides of the immunodominant epitope hMBP (83–99) containing amide or CC bond linked hydrophobic chains for the study of T cell response | |
| Thomas | Synthesis of Canavanine Diamide as a Potential Improvement over Arginine in Cell-Penetrating Peptides | |
| Bhosle | Arginine-rich tat-and (RXR)-motif peptidomimetics for DNA/RNA binding, antimicrobial action and cell penetration | |
| Ivanova et al. | RNA targeting in cells by peptide conjugates of peptide nucleic acids (PNA) |